Dr. Amit Oza is Head of the Division of Medical Oncology & Hematology, and Medical Director of the Cancer Clinical Research Unit at Princess Margaret (PM) Cancer Centre. He is also co-Director of the Drug Development Program at PM Cancer Centre, Scientist at the Ontario Cancer Institute, and Professor of Medicine at University of Toronto. Dr. Oza has been PI and co-investigator in >100 phase I, II and III trials for gynecological cancer and advanced colorectal malignancies. He is the past co-chair of the National Cancer Institute Gynecologic Cancer Steering Committee, and Executive Member of the international Gynecologic Cancer InterGroup. Under his direction, the gynecology group is one of the largest ovarian cancer (OC) clinical trials groups consistently accruing >30% of all patients seen onto clinical trials (>120/yr) at PM Cancer Centre. Under his direction the group has participated or led seminal studies in gynecologic cancers that have led to the approval or use of targeted agents such as PARP inhibitors (olaparib, niraparib) and anti-angiogenic agents (bevacizumab) internationally. Since 2011, he has obtained >$36.9M in peer-reviewed funding and has published >180 articles (all types) in journals, including the New England Journal of Medicine (IF=53); Lancet Oncology (IF=16), and the Journal of Clinical Oncology (IF=16.4).
Cancer. 2015 Jun 10;
Cancer. 2015 Jun 16;
J Clin Oncol. 2015 Jun 15;
Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention.
Gynecol Oncol. 2015 Jun 10;
Expert Opin Drug Saf. 2015 Jun 8;:1-12
Gynecol Oncol. 2015 May 20;
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia.
Gynecol Oncol. 2015 Apr 17;
Lancet Oncol. 2015 Apr 13;
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret Cancer Centre, Chicago and California phase II consortia.
Gynecol Oncol. 2015 Mar 11;
Lancet Oncol. 2015 Jan;16(1):e43-e52
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Co-director, Robert and Maggie Bras and Family Drug Development Program
Professor, Department of Medicine, University of Toronto
Head, Department of Medical Oncology & Hematology